Alembic Pharmaceuticals receives USFDA approval for Doxycycline Capsules

31 Jul 2017 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules USP, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Monodox Capsules, 75 mg and 100 mg, of Aqua Pharmaceuticals. Doxycycline Capsules are indicated for the treatment and prevention of infections that are proven or strongly suspected to be caused by bacteria.

Doxycycline Capsules USP, 75 mg and 100 mg, have an estimated market size of $30 million for twelve months ending December 2016 according to IMS. Alembic now has a total of 62 ANDA approvals (54 final approvals and 8 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.


Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×